Liver Enzymes in Children with beta-Thalassemia Major: Correlation with Iron Overload and Viral Hepatitis
DOI:
https://doi.org/10.3889/oamjms.2015.059Keywords:
Beta thalassemia, egyptian children, viral hepatitis, iron overload, liver enzymesAbstract
BACKGROUND: Beta Thalassemia is the most common chronic hemolytic anemia in Egypt (85.1%) with an estimated carrier rate of 9-10.2%. Injury to the liver, whether acute or chronic, eventually results in an increase in serum concentrations of Alanine transaminase (ALT) and Aspartate transaminase (AST).
AIM: Evaluating the potentiating effect of iron overload & viral hepatitis infection on the liver enzymes.
PATIENTS AND METHODS: Eighty (80) thalassemia major patients were studied with respect to liver enzymes, ferritin, transferrin saturation, HBsAg, anti-HCV antibody and HCV-PCR for anti-HCV positive patients.
RESULTS: Fifty % of the patients were anti-HCV positive and 55% of them were HCV-PCR positive. Patients with elevated ALT and AST levels had significantly higher mean serum ferritin than those with normal levels. Anti-HCV positive patients had higher mean serum ferritin, serum ALT, AST and GGT levels and higher age and duration of blood transfusion than the negative group. HCV-PCR positive patients had higher mean serum ferritin and serum ALT and also higher age and duration of blood transfusion than the negative group.
CONCLUSION: Iron overload is a main leading cause of elevated liver enzymes, and presence of HCV infection is significantly related to the increased iron overload.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Luz A, Sans M, Kimura E, Albuquerque D, et al. α-Thalassemia, HbS, and β-globin gene cluster haplotypes in two Afro-Uruguayan sub-populations from northern and southern Uruguay. Genet Mol Biol. 2006; 29: 595-600. DOI: https://doi.org/10.1590/S1415-47572006000400002
Karimi M, Ghavanini AA, and Kadiva MR. Regional mapping of the Gene frequency of β-Thalassemia in Fars Province, Iran during 1997-1998. Iran J Med Sci. 2000; 25(3&4):134-137.
Ameli M, Besharati S, Nemati K, Zamani F. Relationship between elevated liver enzyme with iron overload and viral hepatitis in thalassemia major patients in Northern Iran. Saudi Med J. 2008; 29(11):1611-5.
Ardalan FA, Osquei MR, Toosi MN, Irvanloo G. Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional study. BMC Gastroenterol. 2004;4:17. DOI: https://doi.org/10.1186/1471-230X-4-17
Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D et al., Hepcidin in iron overload disorders. Blood. 2005; 105: 4103-4105. DOI: https://doi.org/10.1182/blood-2004-12-4844
Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology. 2003;38(3):545–53. DOI: https://doi.org/10.1053/jhep.2003.50389
Khalifa AS, El-Sayed MH, Moustafa AO, Mohammed MM, Rady MS, Salama II. Hepatitis C virus infection in children with hematological diseases: risk factors and reliability of diagnosis assays. Egypt J Pediatr. 2002;19: 293–308.
Omar N, Salama K, Adolf S, El-Saeed GS, et al. Major risk of blood transfusion in hemolytic anemia patients. Blood Coagul Fibrinolysis. 2011; 22(4): 280–4. DOI: https://doi.org/10.1097/MBC.0b013e3283451255
El-Faramawy A, El-Rashidy O, Tawfik P, Hussein G. Transfusion Transmitted Hepatitis: Where Do We Stand Now? A One Center Study in Upper Egypt. Hepat Mon. 2012;12(4): 286-291. DOI: https://doi.org/10.5812/hepatmon.5986
Li CK, Chik K, Lam C, To K et al., Liver disease in transfusion dependent thalassemia major. Arch Dis Child. 2002; 86:344-7. DOI: https://doi.org/10.1136/adc.86.5.344
Cunningham M, Macklin E, Neufeld E, Cohen AR. Thalassemia Clinical Research Network. Complications of β-thalassemia major in North America. Blood. 2004; 104:34-39. DOI: https://doi.org/10.1182/blood-2003-09-3167
Angelucci E, Muretto P, Nicolucci A, Baronciani D et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002; 100:17-21. DOI: https://doi.org/10.1182/blood.V100.1.17
Di Marco V, Capra M, Gagliardotto F, Borsellino Z et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica. 2008; 93(8):1243–1246. DOI: https://doi.org/10.3324/haematol.12554
Dimitrios K, Nikolaos J. Tsagarakis, Evangelia F, Efthimios D, et al. Liver disease in adult transfusion -dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection. Liver International. 2013; 33(3): 420–427. DOI: https://doi.org/10.1111/liv.12095
Edoardo G, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005; 172(3): 367–379. DOI: https://doi.org/10.1503/cmaj.1040752
Ng RH, Brown BA, Valdes R Jr. Three commercial methods for serum ferritin compared and the high-dose "hook effect" eliminated. Clin Chem. 1983;29(6):1109-13. DOI: https://doi.org/10.1093/clinchem/29.6.1109
Burtis CA, Ashford E. Editors, Tietz Textbook of Clinical Chemistry, 2nd ed., Saunders, 1994: 2195.
International federation of clinical chemistry. J Clin Chem Clin Bio. 1980; 18:5231.
Bergmeyer HU. Principles of enzymatic analysis. Verlag chemie (Bergmeyer, H. U., ed.), 1978: 35-40.
Szasz G. New substrates for measuring gamma-glutamyl transpeptidase activity. Z Klin Chem Klin Biochem. 1974;12(5):228.
Hurie M, Mast E, Davis J. Horizontal transmission of hepatitis B virus infection to U.S. born children of Hmong refugees. Pediatrics. 1992; 89: 269-273. DOI: https://doi.org/10.1542/peds.89.2.269
Choo QL, Weiner AJ, Overby Lr, Kuo G et al. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull. 1990;46:423-441. DOI: https://doi.org/10.1093/oxfordjournals.bmb.a072408
Al-Salem AH, Nasserulla Z. Splenectomy for children with thalassemia. Int Surg. 2002; 87: 269-73.
Morsy M, Alnajar A, Almuzainy I, Alhawsawi Z et al. Splenectomized versus non-splenectomized thalassemia patients with thalassemia major. Echocardiographic comparison. Saudi Med J. 2008; 29: 1310-1314.
Taher A, Sheikh-Taha M, Koussa S, Inati I, et al. Comparison between desferrioxamine and deferiprone (L1) in iron-loaded thalassaemia patients. European Journal of Haematology. 2001; 67: 30–34. DOI: https://doi.org/10.1034/j.1600-0609.2001.067001030.x
Pennell DJ, Berdoukas V, Karagiorga M, Ladis V et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006; 107: 3738–3744. DOI: https://doi.org/10.1182/blood-2005-07-2948
Galanello R and Campus S. Defriprone chelation therapy for thalassemia major. Acta Haematol. 2009; 122:155-164. DOI: https://doi.org/10.1159/000243800
El-Alfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol. 2010;32(8):601-5. DOI: https://doi.org/10.1097/MPH.0b013e3181ec0f13
El-Beshlawy A, Mokhtar G, Abd El Ghafar E, Abd El Dayem MS et al. Assessment of Puberty in Relation to L-carnitine and Hormonal Replacement Therapy in β-thalassemic Patients. J Trop Pediatr. 2008; 54: 375-381. DOI: https://doi.org/10.1093/tropej/fmn043
Megahed S, Tayel S, Abdelrahim M, Ali A et al. Role of L-Carnitine in Treatment of β-Thalassemia Major Disease. Journal of Pediatric Sciences. 2011; 3(3):91.
Ruhl CE, Everhart JE. Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology. 2003; 124: 1821-1829. DOI: https://doi.org/10.1016/S0016-5085(03)00395-0
El Gawhary S, Omar N, Abdel Rahman L, Mahmoud M. Hepatic viruses screening in multitransfused Egyptian thalassemia patients. J Arab Child. 2009;20(3):193–202.
Din G, Malik S, Ali I , Ahmed S ,and Dasti JI. Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan. Asian Pac J Trop Med. 2014;7S1:S127-33. DOI: https://doi.org/10.1016/S1995-7645(14)60218-2
Mansour AK, Aly RM, Abdelrazek SY, Elghannam DM, Abdelaziz SM, Shahine DA, Darwish AM, Elmenshawy NM. Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients. Hematol Oncol Stem Cell Ther. 2012;5(1):54-9. DOI: https://doi.org/10.5144/1658-3876.2012.54
Hussein E. Evaluation of infectious disease markers in multitransfused Egyptian children with thalassemia. Ann Clin Lab Sci. 2014;44(1):62-6.
El-Shanshory MR, Kabbash IA, Soliman HH, Nagy HM, Abdou SH. Prevalence of hepatitis C infection among children with β-thalassaemia major in Mid Delta, Egypt: a single centre study. Trans R Soc Trop Med Hyg. 2013;107(4):224-8. DOI: https://doi.org/10.1093/trstmh/trs024
Ocak S, Kaya H, Cetin M, Gali E et al. Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up. Arch Med Res. 2006;37(7):895–8. DOI: https://doi.org/10.1016/j.arcmed.2006.04.007
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
